Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note issued to investors on Monday morning. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of BLPH stock opened at $0.05 on Monday. The stock’s fifty day moving average is $0.05 and its 200-day moving average is $0.06. The stock has a market capitalization of $624,953.00, a PE ratio of -0.06 and a beta of 0.67. Bellerophon Therapeutics has a 52 week low of $0.03 and a 52 week high of $11.15.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.